Biomarker panel for early detection of uterine cancer
Uterine cancer is the most prevalent gynecological malignancy in developed and developing countries and its incidence is arising every year. Worldwide, approximately 382,000 new cases are diagnosed each year and there are an estimated 90,000 deaths. As endometrial cancer becomes more prominent, th...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2024-10-01
|
| Series: | Basic & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://bccr.tums.ac.ir/index.php/bccrj/article/view/500 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863890560155648 |
|---|---|
| author | Nemali Deepthi Deepthi Priya NANDA KUMAR K V DEVARAJAPPAGARI BINDU KASIREDDY LIKHITHA MEKALA SIVA CHARANI |
| author_facet | Nemali Deepthi Deepthi Priya NANDA KUMAR K V DEVARAJAPPAGARI BINDU KASIREDDY LIKHITHA MEKALA SIVA CHARANI |
| author_sort | Nemali Deepthi Deepthi Priya |
| collection | DOAJ |
| description |
Uterine cancer is the most prevalent gynecological malignancy in developed and developing countries and its incidence is arising every year. Worldwide, approximately 382,000 new cases are diagnosed each year and there are an estimated 90,000 deaths. As endometrial cancer becomes more prominent, the need to develop and characterize biomarkers for early-stage diagnosis and the treatment. We analyze the current state of biomarker utilization for early detection, including their sensitivity and specificity, paving the way for timely interventions. Several biomarkers, including P53, K-RAS, CA-125, HER2/neu, HE4, PTEN, MSI are used for early detection, treatment, and prevention of uterine cancer. Prognostic biomarkers in uterine cancer have emerged as indispensable tools for predicting disease progression and patient outcomes. Endometrial biopsy, CT scan, MRI Scan, Dilation and Curettage, Transvaginal ultrasound are vital for diagnosing and staging of uterine cancer and provide essential information about the cancer’s presence, size, and spread, guiding proper treatment decisions. Various treatments modalities, including surgery, Chemotherapy, targeted therapies are examined. In conclusion, early detection through biomarkers like P53, K-RAS, HER2/neu, PTEN, Serum CA-125 holds great promise for early diagnosis and treatment advancements, and offering hope for improved outcomes and a better quality of life for patients in the future.
|
| format | Article |
| id | doaj-art-0ade77b2a49e45f1bef5b006b7bccf76 |
| institution | Kabale University |
| issn | 2228-6527 2228-5466 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Basic & Clinical Cancer Research |
| spelling | doaj-art-0ade77b2a49e45f1bef5b006b7bccf762025-02-09T08:54:20ZengTehran University of Medical SciencesBasic & Clinical Cancer Research2228-65272228-54662024-10-01154Biomarker panel for early detection of uterine cancerNemali Deepthi Deepthi Priya0NANDA KUMAR K V1DEVARAJAPPAGARI BINDU2KASIREDDY LIKHITHA3MEKALA SIVA CHARANI4JNTUAASSOCIATE PROFESSOR, KRISHNA TEJA PHARMACY COLLEGE, TIRUPATHI, INDIA-517506UNDERGRADUATE, KRISHNA TEJA PHARMACY COLLEGE, TIRUPATHI, INDIA-517506UNDERGRADUATE, KRISHNA TEJA PHARMACY COLLEGE, TIRUPATHI, INDIA-517506UNDERGRADUATE, KRISHNA TEJA PHARMACY COLLEGE, TIRUPATHI, INDIA-517506 Uterine cancer is the most prevalent gynecological malignancy in developed and developing countries and its incidence is arising every year. Worldwide, approximately 382,000 new cases are diagnosed each year and there are an estimated 90,000 deaths. As endometrial cancer becomes more prominent, the need to develop and characterize biomarkers for early-stage diagnosis and the treatment. We analyze the current state of biomarker utilization for early detection, including their sensitivity and specificity, paving the way for timely interventions. Several biomarkers, including P53, K-RAS, CA-125, HER2/neu, HE4, PTEN, MSI are used for early detection, treatment, and prevention of uterine cancer. Prognostic biomarkers in uterine cancer have emerged as indispensable tools for predicting disease progression and patient outcomes. Endometrial biopsy, CT scan, MRI Scan, Dilation and Curettage, Transvaginal ultrasound are vital for diagnosing and staging of uterine cancer and provide essential information about the cancer’s presence, size, and spread, guiding proper treatment decisions. Various treatments modalities, including surgery, Chemotherapy, targeted therapies are examined. In conclusion, early detection through biomarkers like P53, K-RAS, HER2/neu, PTEN, Serum CA-125 holds great promise for early diagnosis and treatment advancements, and offering hope for improved outcomes and a better quality of life for patients in the future. https://bccr.tums.ac.ir/index.php/bccrj/article/view/500Endometrial cancerUterine CancerP53PTENK-RASHE4 |
| spellingShingle | Nemali Deepthi Deepthi Priya NANDA KUMAR K V DEVARAJAPPAGARI BINDU KASIREDDY LIKHITHA MEKALA SIVA CHARANI Biomarker panel for early detection of uterine cancer Basic & Clinical Cancer Research Endometrial cancer Uterine Cancer P53 PTEN K-RAS HE4 |
| title | Biomarker panel for early detection of uterine cancer |
| title_full | Biomarker panel for early detection of uterine cancer |
| title_fullStr | Biomarker panel for early detection of uterine cancer |
| title_full_unstemmed | Biomarker panel for early detection of uterine cancer |
| title_short | Biomarker panel for early detection of uterine cancer |
| title_sort | biomarker panel for early detection of uterine cancer |
| topic | Endometrial cancer Uterine Cancer P53 PTEN K-RAS HE4 |
| url | https://bccr.tums.ac.ir/index.php/bccrj/article/view/500 |
| work_keys_str_mv | AT nemalideepthideepthipriya biomarkerpanelforearlydetectionofuterinecancer AT nandakumarkv biomarkerpanelforearlydetectionofuterinecancer AT devarajappagaribindu biomarkerpanelforearlydetectionofuterinecancer AT kasireddylikhitha biomarkerpanelforearlydetectionofuterinecancer AT mekalasivacharani biomarkerpanelforearlydetectionofuterinecancer |